Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Instant alerts for asthma Flare-Ups: a new strategy to tame uncontrolled symptoms?

NCT ID NCT01449409

Disease control Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether automatically identifying people with uncontrolled asthma from electronic health records and immediately notifying both patients and their doctors can lead to better asthma management. Participants are adults and teens with persistent asthma who use inhaled corticosteroids and have recently had signs of poor control, such as frequent rescue inhaler use or steroid courses for flare-ups. The study compares this real-time outreach to standard asthma care to see if it reduces severe exacerbations and improves daily symptom control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Real-time asthma care outreach: automated identification of uncontrolled asthma and immediate notification to patients and physicians, with expedited referral to asthma specialists.
What this could lead to
If effective, this approach could help people with asthma gain better control and reduce severe flare-ups, potentially shaping how healthcare systems deliver timely asthma care.
What could go wrong
The trial is early and relies on administrative data, which may not capture all aspects of asthma control. Benefits may vary across different patient groups, and the intervention's success depends on physician and patient response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2011

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 56 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: KPSC members at time of uncontrolled event: 1. 12-56 years of age 2. Continuously enrolled and with pharmacy benefit for the past year 3. Dispensed inhaled corticosteroid (ICS) in the past 6 months. 4. Uncontrolled asthma: defined within the past year * Impairment cohort: 7th short-acting beta-agonist (SABA) canister dispensed and/or * Risk (exacerbation) cohort: 2nd oral corticosteroid (OCS)dispensing with provider asthma exacerbation encounter within 2 days and at least 1 month after the first OCS dispensing. Exclusion Criteria: * Patients with chronic obstructive lung disease, * emphysema, * cystic fibrosis, * chronic bronchitis, * bronchiectasis, * Churg Strauss, * Wegener's, * sarcoidosis, * pulmonary hypertension or other clinically relevant non-asthma pulmonary disorder such as autoimmunity, * immune deficiency, * cancer, * HIV, * steroid dependent asthma, * omalizumab therapy within the past 3 months, and * requirement for an interpreter.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Kaiser Permanente Southern California Region

    San Diego, California, 92111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.